Nasdaq

Johnson & Johnson Vision Presents Scientific Data Validating Improved Surgical Outcomes With Latest Cataract Innovations And Legacy MGD Treatment At The 2021 ASCRS•ASOA ...

Visual acuity, contrast sensitivity, and depth perception are highly interrelated elements of vision and impact health-related quality of life and safety.4,5 IOL data being presented utilize novel ...
Healio

Waring shares clinical pearls for new Tecnis Synergy

Please provide your email address to receive an email when new articles are posted on . AMELIA ISLAND, Fla. — George O. Waring IV, MD, presented here clinical pearls for the Tecnis Synergy at the ...
Nasdaq

Johnson & Johnson Vision Celebrates 20 Years of Helping Cataract Patients with the See More Campaign and Global Patient Story Search

The TECNIS® portfolio is the broadest mix of IOLs available worldwide, providing solutions for a variety of visual conditions to allow patients to See More In 2021, Johnson & Johnson Vision will ...
Medscape

Crystalens and Multifocals Show Long-term Stability

LOS ANGELES — The accommodative Crystalens intraocular lens (IOL) (Bausch + Lomb) achieved better intermediate visual acuity but not as good near visual acuity compared with the ReStor +3 multifocal ...
Seeking Alpha

Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting

TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes. 5¶ Experience the ...
UUHC Health Feed

Intraocular Lenses

Cataract surgery is a once-in-a-lifetime investment in your eyes that can improve your quality of life for the long term. Advanced lens options can reduce or eliminate the need for glasses after your ...
The Victoria Advocate

Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every ...

"TECNIS Odyssey IOL is the fastest growing PC-IOL in the United States, ^ and we are excited to be making it available to more patients around the world. It addresses a significant unmet need for ...